The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model-Reference-Cited by-同舟云学术

The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model

Published:2021-03-18 Issue:4 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Beredaki Maria-Ioanna¹,Arendrup Maiken Cavling²³⁴^ORCID,Andes David⁵^ORCID,Mouton Johan W.⁶,Meletiadis Joseph¹⁶^ORCID

Affiliation:

1. Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

2. Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark

3. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

4. Department of Clinical Microbiology, University of Copenhagen, Copenhagen, Denmark

5. University of Wisconsin, Madison, Wisconsin, USA

6. Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands

Abstract

Posaconazole is more active than fluconazole against Candida albicans in vitro and is approved for the treatment of oropharyngeal candidiasis but not for that of invasive candidiasis (IC). Here, we explored the efficacy of posaconazole against C. albicans in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model of IC and determined the probability of pharmacodynamic target attainment for the oral solution and intravenous (i.v.)/tablet formulations.

Funder

European Society of Clinical Microbiology and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01292-20

Reference34 articles.

1. EUCAST technical note on posaconazole*

2. In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts

3. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program